search
Documents
N-Glycan Analysis of Infliximab-dyyb
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a Biozen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
N-Glycan Analysis of Infliximab-dyyb
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a Biozen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
Document Type:
Technical Notes
Target Industries:
Techniques:
Brands:
Separation Modes:
HILIC
Phases:
N-Glycan Analysis of Infliximab-dyyb
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a Biozen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
| Target Industries: | Biopharmaceutical Analysis, Pharmaceutical |
| Techniques: | HPLC, HILIC Chromatography, Sample Preparation |
| Brands: | Biozen LC, Biozen SPE |
| Separation Modes: | HILIC |
| Phases: | Biozen-Glycan |
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.